Gene Therapy for Kids’ Deadly Muscle Disease Fails to Reach Trial Goal 

Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep

Catalent Cuts Annual Forecast More Than Expected, Delays Earnings Report Again

Drug Contractor Catalent Plunges After Annual Guidance Cut, Results Delayed